The DOI matches its Crossref record; 109 of the 109 references it cites were found in a registry or an index.
14th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends
Abstract
Antiphospholipid Syndrome (APS) is characterized by vascular thrombosis and/or pregnancy morbidity occurring in patients with persistent antiphospholipid antibodies (aPL). The primary objective of the APS Treatment Trends Task Force, created as part of the 14th International Congress on aPL, was to systematically review the potential future treatment strategies for aPL-positive patients. The task force chose as future clinical research directions: a) determining the necessity for controlled clinical trials in venous thromboembolism with the new oral direct thrombin or anti-factor Xa inhibitors pending the results of the ongoing rivaroxaban in APS (RAPS) trial, and designing controlled clinical trials in other forms of thrombotic APS; b) systematically analyzing the literature as well as aPL/APS registries, and creating specific registries for non-warfarin/heparin anticoagulants; c) increasing recruitment for an ongoing primary thrombosis prevention trial, and designing secondary thrombosis and pregnancy morbidity prevention trials with hydroxychloroquine; d) determining surrogate markers to select patients for statin trials; e) designing controlled studies with rituximab and other anti-B-cell agents; f) designing mechanistic and clinical studies with eculizumab and other complement inhibitors; and g) chemically modifying peptide therapy to improve the half-life and minimize immunogenicity. The report also includes recommendations for clinicians who consider using these agents in difficult-to-manage aPL-positive patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MIYAKIS, S., LOCKSHIN, M. D., ATSUMI, T., BRANCH, D. W., BREY, R. L., CERVERA, R., DERKSEN, R. H. W. M., DE GROOT, P. G., KOIKE, T., MERONI, P. L., et al. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.01753.x · Cited by 7,203
Self-citationKearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
Büller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302507 · Cited by 2,324
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
The Hokusai-VTE Investigators (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306638 · Cited by 1,869
Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome
Legendre, C. M., Licht, C., Muus, P., Greenbaum, L. A., Babu, S., Bedrosian, C., Bingham, C., Cohen, D. J., Delmas, Y., Douglas, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208981 · Cited by 1,586
Dabigatran versus warfarin in patients with mechanical heart valves
Eikelboom, J. W., Connolly, S. J., Brueckmann, M., Granger, C. B., Kappetein, A. P., Mack, M. J., Blatchford, J., Devenny, K., Friedman, J., Guiver, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300615 · Cited by 1,506
ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery
Fleisher, L. A., Beckman, J. A., Brown, K. A., Calkins, H., Chaikof, E. L., Fleischmann, K. E., Freeman, W. K., Froehlich, J. B., Kasper, E. K., Kersten, J. R., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.09.003 · Cited by 1,428
Eerenberg, E. S., Kamphuisen, P. W., Sijpkens, M. K., Meijers, J. C., Buller, H. R., & Levi, M. (2011) · Circulation · doi:10.1161/circulationaha.111.029017 · Cited by 1,361
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
Hillmen, P., Young, N. S., Schubert, J., Brodsky, R. A., Socié, G., Muus, P., Röth, A., Szer, J., Elebute, M. O., Nakamura, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061648 · Cited by 1,303
Treatment and Prevention of Heparin-Induced Thrombocytopenia
Linkins, L.-A., Dans, A. L., Moores, L. K., Bona, R., Davidson, B. L., Schulman, S., & Crowther, M. (2012) · Chest · doi:10.1378/chest.11-2303 · Cited by 1,018
Ridker, P. M., Danielson, E., Fonseca, F. A., Genest, J., Gotto, A. M., Kastelein, J. J., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60447-5 · Cited by 1,010 · cited 1×
“0 mg/dl, rosuvastatin 20 mg daily significantly reduced the occurrence of the firstmajor cardiovascular event and symptomatic venous thromboembolism [76,77].”
BackgroundRuiz-Irastorza, G., Ramos-Casals, M., Brito-Zeron, P., & Khamashta, M. A. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.101766 · Cited by 978
A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism
Glynn, R. J., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900241 · Cited by 752
Revised Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy
Marmor, M. F., Kellner, U., Lai, T. Y. Y., Lyons, J. S., & Mieler, W. F. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2010.11.017 · Cited by 710
Heparin prevents antiphospholipid antibody–induced fetal loss by inhibiting complement activation
Girardi, G., Redecha, P., & Salmon, J. E. (2004) · Nature Medicine · doi:10.1038/nm1121 · Cited by 680
Self-citationHillmen, P., Hall, C., Marsh, J. C. W., Elebute, M., Bombara, M. P., Petro, B. E., Cullen, M. J., Richards, S. J., Rollins, S. A., Mojcik, C. F., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031688 · Cited by 635
Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome
Girardi, G., Berman, J., Redecha, P., Spruce, L., Thurman, J. M., Kraus, D., Hollmann, T. J., Casali, P., Caroll, M. C., Wetsel, R. A., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318817 · Cited by 594
Self-citationComplement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome
Girardi, G., Berman, J., Redecha, P., Spruce, L., Thurman, J. M., Kraus, D., Hollmann, T. J., Casali, P., Caroll, M. C., Wetsel, R. A., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18817 · Cited by 575
Self-citationA Critical Role for Murine Complement Regulator Crry in Fetomaternal Tolerance
Xu, C., Mao, D., Holers, V. M., Palanca, B., Cheng, A. M., & Molina, H. (2000) · Science · doi:10.1126/science.287.5452.498 · Cited by 524
Ritis, K., Doumas, M., Mastellos, D., Micheli, A., Giaglis, S., Magotti, P., Rafail, S., Kartalis, G., Sideras, P., & Lambris, J. D. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.7.4794 · Cited by 489
Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor
Martinoli, J.-L., LeFlem, L., Guinet, C., Plu-Bureau, G., Depasse, F., Perzborn, E., & Samama, M. M. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-03-0176 · Cited by 449
Activation of cultured vascular endothelial cells by antiphospholipid antibodies.
Simantov, R., LaSala, J. M., Lo, S. K., Gharavi, A. E., Sammaritano, L. R., Salmon, J. E., & Silverstein, R. L. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118276 · Cited by 420
Self-citationStohl, W., Hiepe, F., Latinis, K. M., Thomas, M., Scheinberg, M. A., Clarke, A., Aranow, C., Wellborne, F. R., Abud‐Mendoza, C., Hough, D. R., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34400 · Cited by 418
Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus
Ruiz-Irastorza, G., Egurbide, M.-V., Pijoan, J.-I., Garmendia, M., Villar, I., Martinez-Berriotxoa, A., Erdozain, J.-G., & Aguirre, C. (2006) · Lupus · doi:10.1177/0961203306071872 · Cited by 411
Tektonidou, M. G., Laskari, K., Panagiotakos, D. B., & Moutsopoulos, H. M. (2009) · Arthritis Care & Research · doi:10.1002/art.24232 · Cited by 356
Self-citationFleisher, L. A., Beckman, J. A., Brown, K. A., Calkins, H., Chaikof, E., Fleischmann, K. E., Freeman, W. K., Froehlich, J. B., Kasper, E. K., Kersten, J. R., et al. (2008) · Anesthesia & Analgesia · doi:10.1213/01/ane.0000309024.28586.70 · Cited by 350
Eculizumab for Atypical Hemolytic–Uremic Syndrome
Nürnberger, J., Philipp, T., Witzke, O., Saez, A. O., Vester, U., Baba, H. A., Kribben, A., Zimmerhackl, L. B., Janecke, A. R., Nagel, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmc0808527 · Cited by 346
Adhesion mechanism of human beta 2-glycoprotein I to phospholipids based on its crystal structure
Bouma, B. (1999) · The EMBO Journal · doi:10.1093/emboj/18.19.5166 · Cited by 333
Erkan, D. (2002) · Rheumatology · doi:10.1093/rheumatology/41.8.924 · Cited by 330
Self-citationPierangeli, S. S., Colden-Stanfield, M., Liu, X., Barker, J. H., Anderson, G. L., & Harris, E. N. (1999) · Circulation · doi:10.1161/01.cir.99.15.1997 · Cited by 325
Redecha, P., Tilley, R., Tencati, M., Salmon, J. E., Kirchhofer, D., Mackman, N., & Girardi, G. (2007) · Blood · doi:10.1182/blood-2007-01-070631 · Cited by 293
Self-citationJung, H., Bobba, R., Su, J., Shariati‐Sarabi, Z., Gladman, D. D., Urowitz, M., Lou, W., & Fortin, P. R. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27289 · Cited by 291
Improved Postoperative Outcomes Associated with Preoperative Statin Therapy
Hindler, K., Shaw, A. D., Samuels, J., Fulton, S., Collard, C. D., Riedel, B., & Warltier, D. C. (2006) · Anesthesiology · doi:10.1097/00000542-200612000-00027 · Cited by 291
Salmon, J. E., Heuser, C., Triebwasser, M., Liszewski, M. K., Kavanagh, D., Roumenina, L., Branch, D. W., Goodship, T., Fremeaux-Bacchi, V., & Atkinson, J. P. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1001013 · Cited by 285
Self-citationHeparin-Induced Thrombocytopenia Associated with Fondaparinux
(2007) · New England Journal of Medicine · doi:10.1056/nejmc070346 · Cited by 283
Erkan, D., Vega, J., Ramón, G., Kozora, E., & Lockshin, M. D. (2013) · Arthritis & Rheumatism · doi:10.1002/art.37759 · Cited by 279
Self-citationPickering, M. C., de Jorge, E. G., Martinez-Barricarte, R., Recalde, S., Garcia-Layana, A., Rose, K. L., Moss, J., Walport, M. J., Cook, H. T., de Córdoba, S. R., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070301 · Cited by 278
Hunt, J., & Krilis, S. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.152.2.653 · Cited by 269
Berman, H., Rodríguez-Pintó, I., Cervera, R., Morel, N., Costedoat-Chalumeau, N., Erkan, D., Shoenfeld, Y., & Espinosa, G. (2013) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.05.004 · Cited by 259
Self-citationRand, J. H., Wu, X.-X., Quinn, A. S., Ashton, A. W., Chen, P. P., Hathcock, J. J., Andree, H. A. M., & Taatjes, D. J. (2010) · Blood · doi:10.1182/blood-2009-04-213520 · Cited by 253
Complement activation on platelets: Implications for vascular inflammation and thrombosis
Peerschke, E. I., Yin, W., & Ghebrehiwet, B. (2010) · Molecular Immunology · doi:10.1016/j.molimm.2010.05.009 · Cited by 251
Hydroxychloroquine Reverses Thrombogenic Properties of Antiphospholipid Antibodies in Mice
Edwards, M. H., Pierangeli, S., Liu, X., Barker, J. H., Anderson, G., & Harris, E. N. (1997) · Circulation · doi:10.1161/01.cir.96.12.4380 · Cited by 250
Vitamin D in Systemic and Organ-Specific Autoimmune Diseases
Agmon-Levin, N., Theodor, E., Segal, R. M., & Shoenfeld, Y. (2013) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-012-8342-y · Cited by 250
Sacre, K., Criswell, L. A., & McCune, J. M. (2012) · Arthritis Research & Therapy · doi:10.1186/ar3895 · Cited by 246
Kaiser, R., Cleveland, C. M., & Criswell, L. A. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.093013 · Cited by 244
Mok, C. C., Tang, S. S. K., To, C. H., & Petri, M. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21224 · Cited by 237
Guidelines on the diagnosis and management of heparin‐induced thrombocytopenia: second edition
Watson, H., Davidson, S., & Keeling, D. (2012) · British Journal of Haematology · doi:10.1111/bjh.12059 · Cited by 232
Cuadrado, M. J., López‐Pedrera, C., Khamashta, M. A., Camps, M. T., Tinahones, F., Torres, A., Hughes, G. R. V., & Velasco, F. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400509 · Cited by 232
Self-citationAnti-β2 glycoprotein I (β2GPI) autoantibodies recognize an epitope on the first domain of β2GPI
Iverson, G. M., Victoria, E. J., & Marquis, D. M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15542 · Cited by 231
Current concepts on the pathogenesis of the antiphospholipid syndrome
Giannakopoulos, B., Passam, F., Rahgozar, S., & Krilis, S. A. (2007) · Blood · doi:10.1182/blood-2006-04-001206 · Cited by 218
Rand, J. H., Wu, X.-X., Quinn, A. S., Chen, P. P., Hathcock, J. J., & Taatjes, D. J. (2008) · Blood · doi:10.1182/blood-2008-03-144204 · Cited by 215
Costedoat-Chalumeau, N., Amoura, Z., Hulot, J.-S., Aymard, G., Leroux, G., Marra, D., Lechat, P., & Piette, J.-C. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.067835 · Cited by 213
Ota, K., Dambaeva, S., Han, A.-R., Beaman, K., Gilman-Sachs, A., & Kwak-Kim, J. (2014) · Human Reproduction · doi:10.1093/humrep/det424 · Cited by 212
Redecha, P., Franzke, C.-W., Ruf, W., Mackman, N., & Girardi, G. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36089 · Cited by 201
Shapira, I., Andrade, D., Allen, S. L., & Salmon, J. E. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34440 · Cited by 200
Self-citationAtherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus
Urowitz, M. B., Gladman, D., Ibañez, D., Bae, S. C., Sanchez‐Guerrero, J., Gordon, C., Clarke, A., Bernatsky, S., Fortin, P. R., Hanly, J. G., et al. (2010) · Arthritis Care & Research · doi:10.1002/acr.20122 · Cited by 186
Self-citationBlank, M., Shoenfeld, Y., Cabilly, S., Heldman, Y., Fridkin, M., & Katchalski-Katzir, E. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.9.5164 · Cited by 180
Laboratory assessment of new anticoagulants
Samama, M. M., & Guinet, C. (2011) · cclm · doi:10.1515/cclm.2011.134 · Cited by 174
Gharavi, A. E., Pierangeli, S. S., Espinola, R. G., Liu, X., Colden‐Stanfield, M., & Harris, E. N. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10130 · Cited by 174
Eculizumab and Renal Transplantation in a Patient with CAPS
Lonze, B. E., Singer, A. L., & Montgomery, R. A. (2010) · New England Journal of Medicine · doi:10.1056/nejmc0910965 · Cited by 162
Huang, H., Benoist, C., & Mathis, D. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001074107 · Cited by 159
Costedoat-Chalumeau, N., Hulot, J., Amoura, Z., Leroux, G., Lechat, P. P., Funck‐Brentano, C., & Pietté, J. C. (2007) · Rheumatology · doi:10.1093/rheumatology/kel402 · Cited by 159
Iverson, G. M., Reddel, S., Victoria, E. J., Cockerill, K. A., Wang, Y.-X., Martí-Renom, M. A., Šali, A., Marquis, D. M., Krilis, S. A., & Linnik, M. D. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.12.7097 · Cited by 153
Agmon‐Levin, N., Blank, M., Zandman‐Goddard, G., Orbach, H., Meroni, P. L., Tincani, A., Doria, A., Cervera, R., Miesbach, W., Stojanovich, L., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.134817 · Cited by 152
Cosnes, A. (2012) · Archives of Dermatology · doi:10.1001/archdermatol.2011.2558 · Cited by 148
Ferrara, D. E., Liu, X., Espinola, R. G., Meroni, P. L., Abukhalaf, I. K., Harris, E. N., & Pierangeli, S. S. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11449 · Cited by 144
Ferrara, D. E., Swerlick, R. A., Casper, K., Meroni, P. L., Vega-Ostertag, M. E., Harris, E. N., & Pierangeli, S. S. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.00896.x · Cited by 139
Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients
Schmidt‐Tanguy, A., Voswinkel, J., Henrion, D., Subra, J. F., Loufrani, L., Rohmer, V., Ifrah, N., & Belizna, C. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12363 · Cited by 132 · cited 1×
“There were six (30%) venous events in the monotherapy group (n: 20) despite therapeutic range INR and none in the HCQ group (n: 20) during the six month and 36 month followup, respectively [51].”
BackgroundIoannou, Y., Pericleous, C., Giles, I., Latchman, D. S., Isenberg, D. A., & Rahman, A. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22306 · Cited by 132
Self-citationIoannou, Y., Penabad, Z. R., Pericleous, C., Giles, I., Papalardo, E., Vargas, G., Shilagard, T., Latchman, D. S., Isenberg, D. A., Rahman, A., et al. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03316.x · Cited by 132
Self-citationde Leeuw, K., Freire, B. F. A., Smit, A. J., Bootsma, H., Kallenberg, C. G. M., & Bijl, M. (2006) · Lupus · doi:10.1177/0961203306069972 · Cited by 132
Ho, K. T., Ahn, C. W., Alarcón, G. S., Baethge, B. A., Tan, F. K., Roseman, J., Bastian, H. M., Fessler, B. J., McGwin, G., Vilá, L. M., et al. (2005) · Rheumatology · doi:10.1093/rheumatology/kei014 · Cited by 128
Erkan, D., Willis, R., Murthy, V. L., Basra, G., Vega, J., Ruiz‐Limón, P., Carrera, A. L., Papalardo, E., Martínez-Martínez, L.-A., González, E. B., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203622 · Cited by 125
Self-citationDoes hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus?
Wallace, D. J. (1987) · Arthritis & Rheumatism · doi:10.1002/art.1780301219 · Cited by 124
Rituximab treatment for resistant antiphospholipid syndrome.
Rubenstein, E., Arkfeld, D. G., Metyas, S. K., Shinada, S., Ehresmann, S., & Liebman, H. A. (2006) · PubMed · Cited by 120
Prevention of murine antiphospholipid syndrome by BAFF blockade
Kahn, P. J., Ramanujam, M., Bethunaickan, R., Huang, W., Tao, H., Madaio, M. P., Factor, S. M., & Davidson, A. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23764 · Cited by 117
Tripodi, A., Chantarangkul, V., Clerici, M., Negri, B., Galli, M., & Mannucci, P. M. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03178.x · Cited by 104
Erre, G. L., Pardini, S., Faedda, R., & Passiu, G. (2007) · Lupus · doi:10.1177/0961203307085251 · Cited by 103
BRODER, A., & PUTTERMAN, C. (2013) · The Journal of Rheumatology · doi:10.3899/jrheum.120157 · Cited by 102 · cited 1×
“Role of HCQ on the aPL titers Based on limited number of studies, HCQ may decrease antibody levels in aPL positive persons [52]; HCQ use was also associated with lower odds of having persistently positive aPL, adjusted for age, ethnicity, and gender [53].”
BackgroundGlobal effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome
López-Pedrera, C., Ruiz‐Limón, P., Aguirre, M. A., Barbarroja, N., Pérez‐Sánchez, C., Buendía, P., Rodríguez-García, I. C., Rodríguez‐Ariza, A., Collantes‐Estévez, E., Velasco, F., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.135525 · Cited by 92
Self-citationMartinuzzo, M. E., Barrera, L. H., D 'Adamo, M. A., Otaso, J. C., Gimenez, M. I., & Oyhamburu, J. (2014) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12138 · Cited by 91 · cited 1×
“• As with warfarin or heparin (unfractionated or low-molecularweight), ODIs can result in false positive LA test results in assays done with aPTT and dilute Russell viper venom time (dRVVT) reagents [19].”
MethodDetection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time
OS, G. M. A. V., de Laat, B., Kamphuisen, P. W., Meijers, J. C. M., & de Groot, P. G. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04395.x · Cited by 91
Wu, X.-X., Guller, S. M., & Rand, J. H. (2011) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2011.06.064 · Cited by 85
Real world experience with antiphospholipid antibody tests: how stable are results over time?
Erkan, D., Derksen, W. J. M., Kaplan, V, Sammaritano, L., Pierangeli, S. S., Roubey, R., & Lockshin, M. D. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.031856 · Cited by 76
Self-citationMok, M. Y., Chan, E. Y. T., Fong, D., Leung, K. F. S., Wong, W. S., & Lau, C. S. (2005) · PubMed · Cited by 75
Vega-Ostertag, M. E., Liu, X., Henderson, V. J., & Pierangeli, S. S. (2006) · Lupus · doi:10.1191/0961203306lu2315oa · Cited by 72
Rivaroxaban and false positive lupus anticoagulant testing
Kaplan, Z., Butler, J., Malan, E., Gan, E., Tran, H., & Merriman, E. (2010) · Thrombosis and Haemostasis · doi:10.1160/th10-08-0511 · Cited by 71
Khattri, S., Zandman‐Goddard, G., & Peeva, E. (2012) · Autoimmunity Reviews · doi:10.1016/j.autrev.2011.12.011 · Cited by 71
Laboratory monitoring of new anticoagulants
Castellone, D. D., & Cott, E. M. V. (2009) · American Journal of Hematology · doi:10.1002/ajh.21607 · Cited by 69
Predictors of hemoglobin response to eculizumab therapy in paroxysmal nocturnal hemoglobinuria
Dezern, A. E., Dorr, D., & Brodsky, R. A. (2012) · European Journal Of Haematology · doi:10.1111/ejh.12021 · Cited by 68
de la Torre, Y. M., Pregnolato, F., D’Amelio, F., Grossi, C., Simone, N. D., Pasqualini, F., Nebuloni, M., Chen, P. P., Pierangeli, S. S., Bassani, N., et al. (2011) · Journal of Autoimmunity · doi:10.1016/j.jaut.2011.11.009 · Cited by 67
Use of Rituximab in the Antiphospholipid Syndrome
Kumar, D., & Roubey, R. A. S. (2010) · Current Rheumatology Reports · doi:10.1007/s11926-009-0074-5 · Cited by 63
Ames, P. R. J., Matsuura, E., Batuca, J. R., Ciampa, A., Lopez, L., Ferrara, F., Iannaccone, L., & Alves, J. D. (2010) · Lupus · doi:10.1177/0961203309357765 · Cited by 59
Hydroxychloroquine in Prophylaxis of Pulmonary Embolism Following Hip Arthroplasty
JOHNSON, R., & GHARNLEY, J. (1979) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-197910000-00029 · Cited by 57
Vitamin D and antiphospholipid syndrome
Andréoli, L., Piantoni, S., Dall’Ara, F., Allegri, F., Meroni, P. L., & Tincani, A. (2012) · Lupus · doi:10.1177/0961203312446386 · Cited by 57
Pierangeli, S. S., Blank, M., Liu, X., Espinola, R. G., Fridkin, M., Vega-Ostertag, M. E., Roye-Green, K. J., Harris, E. N., & Shoenfeld, Y. (2004) · Journal of Autoimmunity · doi:10.1016/j.jaut.2004.01.002 · Cited by 52
Immunomodulatory effects of HMG-CoA reductase inhibitors.
Danesh, F. R., Añel, R., Zeng, L., Lomasney, J. W., Sahai, A., & Kanwar, Y. S. (2003) · PubMed · Cited by 49
Costa, R., Fazal, S., Kaplan, R. B., Spero, J. A., & da Costa, R. B. (2010) · Clinical Rheumatology · doi:10.1007/s10067-010-1506-3 · Cited by 36
Low levels of vitamin D are common in primary antiphospholipid syndrome with thrombotic disease
Piantoni, S., Andréoli, L., Allegri, F., Meroni, P. L., & Tincani, A. (2012) · Reumatismo · doi:10.4081/reumatismo.2012.307 · Cited by 35
Odiari, E. A., Mulla, M. J., Sfakianaki, A. K., Paidas, M. J., Stanwood, N. L., Gariepy, A. M., Brosens, J. J., Chamley, L., & Abrahams, V. M. (2012) · Human Reproduction · doi:10.1093/humrep/des288 · Cited by 27
Ageno, W., Crowther, M. A., Baglin, T. P., Falanga, A., Buller, H. R., & Palareti, G. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12038 · Cited by 22
Holtan, S. G., Knox, S. K., & Tefferi, A. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.01961.x · Cited by 21
The molecular basis of antiphospholipid syndrome
Gharavi, A. E., Wilson, W., & Pierangeli, S. S. (2003) · Lupus · doi:10.1191/0961203303lu448rr · Cited by 21
Pericleous, C., Miles, J. A., Esposito, D., Garza-García, A., Driscoll, P. C., Lambrianides, A., Latchman, D. S., Isenberg, D. A., Rahman, A., Ioannou, Y., et al. (2011) · Molecular Immunology · doi:10.1016/j.molimm.2011.07.024 · Cited by 18
Self-citationLauvao, L. S., Goshima, K. R., León, L. R., Nolan, P. E., & Hughes, J. (2008) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2008.02.052 · Cited by 9
Komuro (2001) · doi:10.1002/1529-0131(200112)44:12
Cited by
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome
Pengo, V., Denas, G., Zoppellaro, G., Jose, S. P., Hoxha, A., Ruffatti, A., Andreoli, L., Tincani, A., Cenci, C., Prisco, D., et al. (2018) · Blood · doi:10.1182/blood-2018-04-848333 · Cited by 822
ATUALIZAÇÃO DA DIRETRIZ BRASILEIRA DE DISLIPIDEMIAS E PREVENÇÃO DA ATEROSCLEROSE - 2017
Faludi, A., Izar, M., Saraiva, J., Chacra, A., Bianco, H., Afiune Neto, A., Bertolami, A., Pereira, A., Lottenberg, A., Sposito, A., et al. (2017) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20170121 · Cited by 633
Neutrophil extracellular traps (NETs) in autoimmune diseases: A comprehensive review
Lee, K. H., Kronbichler, A., Park, D. D.-Y., Park, Y., Moon, H., Kim, H., Choi, J. H., Choi, Y., Shim, S., Lyu, I. S., et al. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.09.012 · Cited by 624
Cohen, H., Hunt, B. J., Efthymiou, M., Arachchillage, D. R. J., Mackie, I. J., Clawson, S., Sylvestre, Y., Machin, S. J., Bertolaccini, M. L., Ruiz-Castellano, M., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)30079-5 · Cited by 410
Self-citationYalavarthi, S., Gould, T. J., Rao, A. N., Mazza, L. F., Morris, A. E., Núñez‐Álvarez, C., Hernández‐Ramírez, D., Bockenstedt, P. L., Liaw, P. C., Cabral, A. R., et al. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39247 · Cited by 391
Metadata
- Authors
- Erkan, D., Aguiar, C. L., Andrade, D., Cohen, H., Cuadrado, M. J., Danowski, A., Levy, R. A., Ortel, T. L., Rahman, A., Salmon, J. E., Tektonidou, M. G., Willis, R., & Lockshin, M. D.
- Venue
- Autoimmunity Reviews
- Publisher
- Elsevier BV
- Published
- 2014-06
- Volume
- 13
- Issue
- 6
- Pages
- 685-696
- ISSN
- 1568-9972 (ISSN-L)
- OpenAlex
- W2030684251
- Cited by
- 322
- References
- 109
- FWCI
- 42.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.